Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors.

Cancer immunology research·2026

Same author

Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Taking "Multiple Shots on Goal" with an Armed Invariant NK Cell Approach.

Cancer immunology research·2026

Same author

A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> models.

Oncoimmunology·2025

Same author

A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.

Nature biotechnology·2025

Same author

PD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma.

Cancer research communications·2025

Same journal

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML.

Molecular therapy oncolytics·2025

Same journal

<i>Molecular Therapy Oncology</i>: What's in a name?

Molecular therapy oncolytics·2023

Same journal

New advances in cancer therapy targeting TGF-β signaling pathways.

Molecular therapy oncolytics·2023

Same journal

miR-146a: Overcoming coldness in ovarian cancer.

Molecular therapy oncolytics·2023

Same journal

The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges.

Molecular therapy oncolytics·2023

Same journal

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.

Molecular therapy oncolytics·2023

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptor T-cell therapy for solid tumors.

Kheng Newick¹, Edmund Moon¹, Steven M Albelda¹

¹Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania, USA.

Molecular Therapy Oncolytics

|May 11, 2016

Summary

This summary is machine-generated.

CAR T-cell therapy shows promise against blood cancers but faces significant challenges in solid tumors. This review explores the key obstacles hindering CAR T-cell efficacy in the solid tumor microenvironment.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Mar 21, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptor (CAR) T cells are engineered immune cells designed to target cancer.
CAR T-cell therapy has achieved remarkable success in treating hematological malignancies.
Translating this success to solid tumors remains a significant challenge in cancer immunotherapy.

Purpose of the Study:

To review the key hurdles limiting CAR T-cell effectiveness in the solid tumor microenvironment.
To highlight current research directions for overcoming these challenges.

Main Methods:

Literature review of CAR T-cell therapy in solid tumors.
Analysis of the tumor microenvironment's impact on CAR T-cell function.
Discussion of factors affecting T-cell persistence and activity.

Main Results:

CAR T cells face multiple barriers in solid tumors, including antigen heterogeneity, immune suppression, and poor T-cell infiltration and persistence.
The tumor microenvironment actively inhibits CAR T-cell function.

Conclusions:

Overcoming the challenges in the solid tumor microenvironment is crucial for expanding CAR T-cell therapy.
Further research is needed to enhance CAR T-cell persistence, infiltration, and activity in solid tumors.